Press Releases

YEAR
Toggle Summary Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
DUBLIN, Ireland and FORT WASHINGTON, Pa. , April 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that the first patient was
View HTML
Toggle Summary Nabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
-Total revenue of $9.3 million driven by continued SIVEXTRO prescription growth- -Net product sales increased 8% sequentially in Q4 2021 versus Q3 2021- -Cash runway extended well into Q4 2022- -Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland , March 29, 2022 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa. , March 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , March 01, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted a non-statutory stock
View HTML
Toggle Summary Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022
—   Meeting to Reconvene on March 24, 2022 — DUBLIN, Ireland and FORT WASHINGTON, Pa. , Jan. 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious
View HTML
Toggle Summary Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders
— Meeting to Reconvene on January 18, 2022 — DUBLIN, Ireland and FORT WASHINGTON, Pa. , Jan. 14, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious
View HTML
Toggle Summary Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021
-SIVEXTRO ® (tedizolid phosphate) remains on track for return to historical peak sales by mid-2022- -XENLETA ® (lefamulin) Phase I Cystic Fibrosis (CF) trial on track to enroll first patient in Q122- -Cash resources of $47.7 million as of 12/31/21 provides cash runway well into Q422- DUBLIN,
View HTML
Toggle Summary Nabriva Therapeutics to Adjourn Extraordinary General Meeting of Shareholders on December 22, 2021
— Meeting to Reconvene on January 14, 2022 — DUBLIN, Ireland and FORT WASHINGTON, Pa. , Dec. 22, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious
View HTML
Toggle Summary Nabriva Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Dec. 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder ,
View HTML
Toggle Summary Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Nov. 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner,
View HTML

For Media Inquiries

E-mail: PR@nabriva.com


For Investor Relations

E-mail: IR@nabriva.com